Innovative Projects in Early Stage Roadshow

13:30 - 17:30
  • 早期项目路演专场
  • Innovative Projects in Early Stage Roadshow
  • Moderator
  • 袁清慧 , 中信建投证券制药及生物科技组首席分析师
  • YUAN Qinghui , Head of Pharmaceutical and Biotechnology Industry Equity Research at China Securities
13:30 - 13:50
  • 项目 1
  • Project 1
  • 释放机体先天免疫机制为包括阿尔兹海默症的多类疾病开发探索创新疗法
  • Developing Novel Therapeutics by Harnessing Innate Immunity and Its Intervening Role for Multiple Diseases’ Pathology Including Alzheimer’s Disease
  • 黄悦 Plasmotact Therapeutics Limited HK首席科学官、首席运营官
  • HUANG Yue , CSO & COO, Plasmotact Therapeutics Limited HK
13:50 - 14:10
  • 项目 2
  • Project 2
  • 抗菌多肽药物AL-Dap3
  • A Peptide Antibiotic Candidate Dap3
  • 李卓荣 中国医学科学院医药生物技术研究所教授
  • LI Zhuorong , Professor, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences
14:10 - 14:30
  • 项目 3
  • Project 3
  • 用于治疗转移性胰腺癌的新型胆碱代谢小分子抑制剂CHKI-03的新药研发
  • Novel Drug Development of CHKI-03: A New Small-Molecule Inhibitor Targeting Choline Metabolism for the Treatment of Metastatic Pancreatic Cancer
  • 郭俊超 中国医学科学院北京协和医院主任
  • GUO Junchao , Director, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
14:30 - 14:50
  • 项目 4
  • Project 4
  • 第二代自研药械组合产品(人脱细胞羊膜支架+脐带间充质干细胞)
  • The Next-Gen Drug-Device Combination Product (Human Acellular Amniotic Membrane Scaffold + hUC-MSCs)
  • 张旭 瑞因细胞工程科技(广州)有限公司首席执行官
  • ZHANG Xu , CEO, Goodwill Cell Engineering Technology (Guangzhou) Co., Ltd.
14:50 - 15:10
  • 项目 5
  • Project 5
  • 颠覆杜氏肌营养不良症治疗的新一代基因疗法
  • Transforming Duchenne Muscular Dystrophy Treatment by Delivering Next-Gen DMD Gene Therapy
  • 马一介 北海康成制药有限公司商务拓展和外部创新副总裁
  • EJ MA , VP of Business Development and External Innovation, CANbridge Pharmaceuticals
15:10 - 15:30
  • 项目 6
  • Project 6
  • 基于mRNA的广谱治疗性疫苗产业化转化项目汇报
  • Developing Broad-Spectrum Therapeutic Cancer Vaccines (BSTCV) for Solid Tumors
  • 黄建东 香港大学生物医学系合成生物学讲席教授
  • HUANG Jiandong , Chair Professor of Synthetic Biology, The University of Hong Kong
15:30 - 15:50
  • 项目 7
  • Project 7
  • 镇静催眠候选药物YZG-331
  • Sedative-Hypnotic Candidate YZG-331
  • 郭庆兰 中国医学科学院药物研究所副研究员
  • GUO Qinglan , Associate Researcher, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College
15:50 - 16:10
  • 项目 8
  • Project 8
  • 首创高效治疗宫颈癌及癌前病变的原研DRIPs抑制剂开发
  • Development of a Highly Efficacious First-in-Class Vaginal Gel Targeting DRIPs for Cervical Cancer and Precancerous Lesions
  • 梁纯 香港科技大学教授
  • LIANG Chun , Professor, The Hong Kong University of Science and Technology
16:10 - 16:30
  • 项目 9
  • Project 9
  • 颠覆IBD治疗格局:调节miRNA的小分子创新药H021
  • A Novel Small Molecule Drug H021 Mediates miRNA, Potential to be the Best Treatment of IBD
  • 王超磊 江苏柯菲平医药股份有限公司研发技术总监
  • WANG Chaolei , R&D Director, Jiangsu Carephar Pharmaceutical Co., Ltd.
16:30 - 16:50
  • 项目 10
  • Project 10
  • NTQ5082——具备BIC潜力的小分子CFB抑制剂
  • NTQ5082——A Small-Molecule CFB Inhibitor with BIC Potential
  • 季晓君 南京正大天晴制药有限公司转化医学负责人
  • JI Xiaojun , Head of Translational Medicine, Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd.
16:50 - 17:10
  • 项目 11
  • Project 11
  • 衰老相关疾病治疗
  • Treatment of Aging-Related Diseases
  • 姬伟 源生生物科技(青岛)有限责任公司首席执行官
  • Jason JI , CEO, Orisomes Biotech
17:10 - 17:30
  • 项目 12
  • Project 12
  • 产品化的通用型CAR-T细胞及记忆NK细胞治疗药物
  • Development of Productized off-the-shelf CAR-T and Memory NK Cell Therapy
  • 方宏亮 上海晨泰森豪科技有限公司首席研发官
  • Howard FANG , Chief Development Officer,Shanghai Alpha Biopharma Co., Ltd.